federal_register: 2024-23418
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts | regulation_id_numbers |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-23418 | Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program Final Guidance | Notice | The Centers for Medicare & Medicaid Services (CMS) is announcing the availability of CMS' final guidance for the second cycle of the Medicare Drug Price Negotiation Program and manufacturer effectuation of the maximum fair price in 2026 and 2027 for the implementation of the Inflation Reduction Act. This and other Inflation Reduction Act-related guidance can be viewed on the dedicated Inflation Reduction Act section of the CMS website at https://www.cms.gov/ inflation-reduction-act-and-medicare/. | 2024-10-10 | 2024 | 10 | https://www.federalregister.gov/documents/2024/10/10/2024-23418/inflation-reduction-act-ira-medicare-drug-price-negotiation-program-final-guidance | https://www.govinfo.gov/content/pkg/FR-2024-10-10/pdf/2024-23418.pdf | Health and Human Services Department; Centers for Medicare & Medicaid Services | 221,45 | The Centers for Medicare & Medicaid Services (CMS) is announcing the availability of CMS' final guidance for the second cycle of the Medicare Drug Price Negotiation Program and manufacturer effectuation of the maximum fair price in 2026 and 2027 for... |